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Abstract Purpose: Purpose of this study has been the assessment of nuclear factor-nB (NF-nB) as a
survival factor in humanmesothelial cells (HMC), transformed HMC andmalignantmesothelioma
(MMe) cells.We aimed at verifyingwhether the proteasome inhibitor Bortezomib could abrogate
NF-nB activity in MMe cells, leading to tumor cell death and may be established as a novel
treatment for this aggressive neoplasm.
Experimental Design: In HMC and MMe cells, NF-nB nuclear translocation and DNA binding
were studied by electrophoretic mobility shift assay, following treatment with tumor necrosis
factor-a (TNF-a). The IKK inhibitor Bay11-7082 was also tested to evaluate its effects on HMC,
transformed HMC, and MMe cell viability upon exposure to asbestos fibers. Following Bortezo-
mib treatment, cytotoxicity of MMe cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, whereas apoptosis and cell-cycle blockade were investigated by
high-content analysis. Bortezomib was also given to mice bearing i.p. xenografts of MMe cells,
and its effects on tumor growth were evaluated.
Results:Here, we show that NF-nBactivity is a constitutive survival factor in transformed HMC,
MMe cells, and acts as a survival factor in HMC exposed to asbestos fibers. Bortezomib inhibits
NF-nB activity in MMe cells and induces cell cycle blockade and apoptosis in vitro as well as
tumor growth inhibition in vivo.
Conclusions: Inhibition of NF-nB constitutive activation in MMe cells by Bortezomib resulted in
in vitro cytotoxicity along with apoptosis and in vivo tumor regression. Our results support the
use of Bortezomib in the treatment ofMMe andhas led to a phase II clinical trial currently enrolling
in Europe.
Malignant Mesothelioma (MMe) is a primary pleural and
peritoneal cancer related to asbestos exposure. Epidemiologic
data show that in the next 30 years, this disease will cause a
quarter of a million of deaths in Europe in men who have been
occupationally exposed to asbestos fibers (1). In the United
States, MMe has already increased in frequency by 90% during
the last two decades, and currently,f4,000 deaths per year are
attributed to this disease (2). Rarely suitable for radical surgical
resection and usually resistant to both radiotherapy and
chemotherapy, MMe is denoted by a very poor prognosis, with
a median survival of 12 to 18 months from diagnosis (3).
Clearly, effective systemic treatment options are needed for this
disease.
Among the numerous factors involved in the resistance of
cancer cells to death, the transcriptional factor NF-nB seems to
play a relevant role. NF-nB promotes cell survival by activating
transcription of target genes normally repressed by binding of
the specific inhibitor InB, which sequesters the NF-nB p50/p65
heterodimer in the cytoplasm (4). Inhibition is reversed in
response to several intracellular stimuli, resulting in targeted,
ubiquitin/proteasome-mediated degradation of InB (5, 6). Free
NF-nB then translocates to the nucleus to activate genes
protecting the cell from apoptosis, promoting cell growth and
differentiation, and inducing synthesis of angiogenic factors
(4). Deregulation of NF-nB signaling control is an important
feature of a number of human hematological malignancies and
solid tumors, including head and neck, pancreatic, colon,
breast, and non–small cell lung carcinomas (7–12). Moreover,
activation of the NF-nB pathway can stimulate proliferation and
reduce the effectiveness of chemotherapy and ionizing radia-
tion (13, 14).
Bortezomib (already known as PS-341, Velcade2) is a potent
and selective inhibitor of the 20S proteasome (15). The actions
of Bortezomib are pleiotropic and include inhibition of NF-nB
activation by preventing InB degradation. In vitro and mouse
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xenograft studies have clearly shown that this molecule
possesses antitumor activity in a variety of human cancers
(16), and Bortezomib received approval from the U.S. Food
and Drug Administration (FDA), for second-line therapy of
patients with progressive multiple myeloma. The importance of
the ubiquitin proteasome system has been identified in
peritoneal mesothelioma cells where Bortezomib, in combina-
tion with oxaliplatin, has shown preclinical activity (17);
similarly, another proteasome inhibitor (PSI) has demonstrated
in vitro efficacy on MMe cells (18).
Here, we report that NF-nB acts as a survival factor in human
mesothelial cells (HMC) exposed to asbestos fibers, and that
Bortezomib antagonizes constitutive NF-nB activity in MMe
cells, exerting in vitro cytotoxicity. Evidence is provided for the
first time in vivo, demonstrating potent activity of Bortezomib
against MMe xenografts. These results have provided a rationale
for using Bortezomib as a novel treatment for MMe therapy,
which is currently being evaluated in European multicenter
phase II clinical trials.
Materials andMethods
Cell lines and culture conditions. The malignant mesothelioma cell
line REN was generously provided from Dr. Steven Albelda (University
of Pennsylvania, Philadelphia, PA; ref. 19). The MMB and MMP cell
lines have been derived from pleural effusions of patients with MMe
and stabilized in culture. Normal HMCs are an early-passage primary
cell line derived from transudative pleural fluid of a patient with heart
failure. Mesothelial origin of all the lines was confirmed by
immunocytochemistry using antibodies against cytokeratin, vimentin,
calretinin, and carcinoembryonic antigen (CEA). A profile of cytoker-
atin, vimentin, calretinin positivity, and CEA negativity was established
as criteria of mesothelial origin, as previously described (20). MMe cells
were maintained in RPMI 1640 containing 10% fetal bovine serum
(FBS), whereas HMC cells were cultured using OptiMEM containing
20% FBS. All cell lines were cultured at 37j in a humidified incubator in
an atmosphere of 5% CO2. Under these growth conditions, the
doubling time was f24 h for the REN, MMB, and MMP cell lines and
f36 h for HMC.
Asbestos fibers. Amosite fibers from the Unio Internationale Contra
Cancrum were suspended in PBS at 2.0 mg/mL and then triturated eight
times through a 22-gauge needle and autoclaved. Cells were cultured for
24 h in medium containing 2% FBS, supplemented with 10 Ag/cm2
amosite fibers. Also, a long-term exposure was done by culturing cells
for 60 days, after two cycles of treatment, 72 h each, with low
concentrations (2 or 5 Ag/cm2) of amosite fibers, as previously
described (20).
Drug and reagents. For in vitro studies, Bortezomib (Millennium
Pharmaceutical Inc.) was reconstituted in DMSO at a concentration of
1mmol/L and serially diluted in normal saline to achieve a concentration
of 1 Amol/L. For in vivo evaluation of antitumor activity, injectable Bor-
tezomib (3.5 mg per 10-mL vial) was diluted in normal saline to achieve
a solution of 25 Ag/mL.Mice received i.p. injections of 100 AL per 2.5 g of
mouse body weight or 50 AL per 2.5 g of body weight of this solution
to achieve doses of 1.0 or 0.5 mg/kg, respectively. In vitro studies of the
signaling pathway leading to NF-nB binding activity were done using
inhibitors of phosphoinositide-3-kinase (PI3K; wortmannin), Erk2
(PD98059), p38 (PD169316), c-Src (PP2), and IKK (Bay 11-7082), all
from Sigma. Serum-starved cells were treated with purified recombinant
human HGF (50 ng/mL; R&D Systems Inc.) for 15 min in serum-free
medium. For the NF-nB nuclear translocation assay, the exportin
inhibitor leptomycin B (LMB; from Sigma) was used as a control.
RPMI 1640 cell culture growth medium, trypsin, and FBS were
purchased from Life Technologies. Electrophoretic mobility shift assay
(EMSA) reagents and the probe set for NF-nB were purchased from
Panomics. Monoclonal antibodies to phospho–NF-nB antibodies were
purchased from Cell Signaling Technology, whereas human poly(ADP-
ribose)-polymerase (PARP) was purchased from Zymed Laboratories.
Reagents for SDS-PAGE were purchased from Bio-Rad Laboratories. For
immunocytochemistry, anti-active caspase-3 antibody was purchased
from Promega; anti-cyclin B1 antibody and monoclonal anti–NF-nB
p65RelA antibody were purchased from Santa Cruz Biotechnology; anti-
rabbit Cy22- and anti-mouse Cy25-conjugated secondary antibodies
were obtained from Amersham Biosciences; anti-bromodeoxyuridine
(BrdUrd) antibody and nuclease reagent were obtained within the Cell
Proliferation Fluorescence Kit (Amersham Biosciences); recombinant
tumor necrosis factor-a (TNF-a), BrdUrd, and 4¶,6-diamidino-2-
phenylindole (DAPI) were obtained from Sigma-Aldrich. All other
chemicals were purchased from Sigma.
Cytotoxicity assay. Evaluation of the cytotoxic effect of Bortezomib
was done using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT)–based semiautomated colorimetric assay that
assessed mitochondrial activity. Briefly, 3  103 cells were plated into
each well of a 96-well flat-bottom plate (Costar, Corning Incorporated)
in 100 AL of RPMI 1640 containing 10% FBS. After 24 h, Bortezomib
was added to each well to achieve a final concentration of 0 to
100 nmol/L. After an additional 72 h, 100 AL of a 5-mg/mL MTT
solution diluted in PBS was added to each well, and the plate was
incubated for 2 h at 37jC. Plates were centrifuged at 200  g for
10 min, and the resulting supernatant in each well was aspirated and
replaced with 100 AL of DMSO. After gentle shaking for 5 min, the
absorbance of each well at 550 nm was determined using a Dynatech
MR-500 plate reader. Cells not exposed to the drug or medium
containing no cells were used as positive or negative controls,
respectively. An absorbance twice that of the negative control was
considered positive for the presence of viable cells.
Fluorescence immunocytochemistry and high-content analysis. Cells
were seeded at a density of 8  103 cells per well in 96-well poly-
L-lysine–coated clear-bottomed plates (Matrix Technologies) and
cultured overnight. After treatment with compounds for the indicated
time points, 50 Amol/L BrdUrd was added to the medium for 15 to
20 min, and then cells were fixed with 3.7% (v/v) formaldehyde for
20 min and permeabilized with 0.3% (v/v) Triton X-100 (Sigma-
Aldrich) in PBS for 15 min. Cells were alternatively immunostained
with anti-BrdUrd, anti–cyclin B1, and anti-active caspase-3 antibodies
and counterstained with DAPI. BrdUrd incorporation and cyclin B1
represent well-characterized markers of active S-phase and G2-M phase,
respectively (21), whereas active caspase-3 is a specific apoptotic marker
(22). For immunostaining procedure, cells were saturated with 1%
(w/v) bovine serum albumin (BSA) for 1 h, and then primary antibody
was added at the manufacturer’s recommended dilution in PBS
containing 1% (w/v) BSA and 0.3% (v/v) Tween-20 (Sigma-Aldrich)
for 1 h at 37jC. The antibody solution was removed, and cells were
washed twice with PBS. For BrdUrd incorporation analysis, anti-BrdUrd
primary antibody was added diluted 1:100 in nuclease solution. Cells
were then washed twice with PBS, and secondary antibody was added
diluted 1:500 in PBS containing 1% (w/v) BSA, 0.3% (v/v) Tween-20,
and 1 Ag/mL DAPI for 1 h at 37jC. After incubation, cells were washed
twice with PBS, and 200 AL PBS were left in each well. The ArrayScan
HCA reader (Thermo Fisher Scientific Inc.), used to quantify cellular
parameters by fluorescence staining, has been previously described
(21). A quadruple band fluorescence XF93 excitation filter (Omega
Optical) was used to acquire images in the DAPI, green or far-red
channels with a 10 objective by exposing fields for fixed times. For
each sample, at least 10 fields were automatically acquired and
analyzed by the ArrayScan software, corresponding to at least 500
cells. Each single cell was recognized, counted, and accepted for
subsequent analysis on the basis of its nuclear DAPI fluorescence. The
Cytotoxicity I and Nuclear Translocation bioapplications (Thermo
Fisher Scientific Inc.) were used to quantify the intensity of nuclear and
cytoplasmic fluorescence in each single cell. Cell number was also
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quantified for each dose of compound on the basis of their nuclear
DAPI staining and reported as percentage of cells scored in 10 fields
with respect to untreated controls (normalized at 100%). EC50 values
were estimated from dose-response curves by nonlinear regression
analysis.
EMSA. DNA binding of NF-nB in HMC and MMe cells (3 to 5 
106) was evaluated at basal conditions (MMP, MMB, and REN versus
MLP29) following exposure either to asbestos fibers in medium (MMB
and REN), in the presence or absence of Bay 11-7082 or in medium
containing 25 and 100 nmol/L Bortezomib up to 48 in comparison with
Bay 11-7082 (MMB and REN). Nuclear extracts were prepared as
previously described (23). About 5 Ag of the nuclear extract were prein-
cubated for 10 min at room temperature in binding buffer [50 mmol/L
Tris-HCl (pH 7.4), 250 mmol/L NaCl, 2.5 mmol/L EDTA, 2.5 mmol/L
DTT, 20% glycerol, 5 mmol/L MgCl2] supplemented with 2 Ag of
poly(dI-dC).poly(dI-dC); Amersham. This mixture was subsequently
incubated in a total volume of 20 AL at room temperature with g-32P-
ATP–labeled oligonucleotide probe (Promega Corporation), corres-
ponding to the human consensus NF-nB site. DNA-protein complexes
were resolved on a 6% nondenaturing polyacrylamide gel in 0.5% Tris-
borate-EDTA, and the labeled complexes were visualized by autoradi-
ography.
NF-kB nuclear translocation analysis. NF-nB p65RelA translocation
across the nuclear envelope was analyzed in MMP and REN cells by
high-content analysis (HCA). Pretreatment with inhibitors was done for
4, 8, or 24 h, then 4 ng/mL TNF-a was added, and cells were incubated
with inhibitors for an additional 1 h.
After treatments for the indicated times, cells were immunostained
with an anti–NF-nB antibody and counterstained with DAPI. The
ArrayScan reader was used to acquire images of at least 200 cells in each
sample and to quantify the difference between the intensity of nuclear
and cytoplasmic NF-nB–associated fluorescence (Nuc-Cyto Diff),
reported as translocation parameter as previously described (24).
Immunoblotting. About 1  106 cells were seeded into separate
75-cm2 tissue culture flasks containing 20 mL of medium plus serum.
Twenty-four hours later, Bortezomib was added at concentrations of
0 to 100 nmol/L. Cells were harvested by trypsinization 24 and
48 h after the addition of the drug, and cell extracts were prepared in a
cell lysis buffer containing 50 mmol/L Tris (pH, 7.4), 150 mmol/L NaCl,
0.1% Triton X-100, 0.1% Nonidet P-40, 4 mmol/L EDTA, 50 mmol/L
NaF, 0.1 mmol/L NaV, 1 mmol/L DTT, and 10 mg/mL each of the
protease inhibitors antipain, leupeptin, pepstatin A, chymostatin, and
50 mg/mL phenylmethylsulfonyl fluoride (PMSF). Protein concentration
of cell extracts was determined (Bio-Rad), and aliquots containing equal
amounts of protein were separated by SDS-PAGE and then transferred to
nitrocellulose membrane. Filters were then processed and probed with
appropriate antibodies to detect PARP. Protein-antibody complexes were
visualized by enhanced chemiluminescence.
Animals and xenograft murine model. In vivo studies were carried
out in 4- to 6-week-old male beige, nude, Xid mice obtained from
Harlan Sprague-Dawley, with animals maintained under pathogen-free
conditions. Mice received a single i.p. injection of 1.3 to 1.6  107 REN
cells in a volume of 1 mL serum-free media, and Bortezomib therapy
was initiated 3 days later at the dosage described above. Preliminary
experiments revealed that mice injected with 1.3 to 2.0  107 cells
developed small i.p. tumor masses within 15 days following tumor
cell injection and progressed to multiple small mesenteric tumor
nodules by day 22. By day 28, 75% of injected mice contained large
peri-pancreatic tumors (1.0-1.5 cm) with multiple mesenteric nodules,
bloody ascites, and diaphragmatic tumors. By day 35, more than
95% of the animals present very large, bulky peri-pancreatic tumors
(2.0-2.5 cm), numerous large mesenteric nodules, large amounts of
bloody ascites, and bulky diaphragmatic involvement. Mean survival
in untreated animals in these previous studies was 68 days (range,
63-74 days; ref. 25). For scoring purposes in this study, we defined
diaphragmatic involvement at the time of sacrifice (day 30 after tumor
cell injection) as ‘‘none’’ if no tumoral involvement was macroscopi-
cally detectable, ‘‘mild’’ if only few tumoral nodules were detectable and
covered less than one-third of the surface of the diaphragm, ‘‘moderate’’
if tumoral nodules accounted for one-third to two thirds of the surface,
and ‘‘massive’’ if dissemination of tumoral masses covered more than
two-thirds of the surface.
All animal experiments were done in accordance with institutional
animal committee guidelines. Mice were maintained and handled
under aseptic conditions, and animals were allowed access to food and
water ad libitum. The study was repeated.
Statistics. In vitro data were expressed as meanF SD of at least three
independent experiments. Statistical differences were evaluated by
Student’s t test, with significance threshold of at least 95% confidence
or higher. All statistical tests were two sided. For statistical analysis of
the in vivo results, we assessed drug effectiveness by three measures
taken at the termination of each trial: (a) tumor weight, (b) ascite
volume, and (c) the extent of diaphragm involvement, classified as
none, mild, moderate, or massive as described above.
We assessed ascite volume on a dichotomous scale, assigning
volumes of traces or greater as positive and volumes of 0 as negative.
For parametric analyses, we used log-transformed values of tumor
weight; to address zero values, 0.01 mg/kg was added to each tumor-
weight value before the transformation. We used the Kruskal-Wallis test
of equality of populations to assess for differences among the ranked
values of diaphragm involvement. Because there were no statistically
significant differences among the two trials in measures (by treatment
class) of ascite or diaphragm involvement, we assessed treatment
differences of these measures within and across trials; because of a
significant difference in tumor weight between trials, we did within-trial
analyses only for this measure.
Results
NF-kB is an intrinsic survival factor in MMe cells and in HMC
when exposed to asbestos fibers. To determine the state of
NF-nB activation in HMC, DNA binding assay was conducted;
DNA binding was barely detectable in HMC, whereas it was
constitutive in MMe cells MMP, MMB, and REN (Fig. 1A). HGF
is one of the most important growth factors involved in
mesothelial transformation, mainly upon autocrine loop (26);
thus, we assessed the effect of HGF exposure on NF-nB in HMC
cells. In contrast to what previously observed in epithelial
MLP29 cells (23), NF-nB DNA binding was not increased by
HGF, suggesting a different, cell type–dependent mechanism of
NF-nB activation. Cell treatment with Bay 11-7082, a known
inhibitor of InB-a phosphorylation, resulted in the substantial
reduction of NF-nB activity in MMe cells (Fig. 1A). On the
contrary, inhibitors of tyrosine kinase activity (Genistein), of
Src (PP2), of Erk2 (PD98059), of PI3K/Akt (wortmannin), and
of p38 (SB203580) did not affect NF-nB DNA binding in any
cell type tested (Fig. 1B).
The intracellular localization ofNF-nB complexeswas analyzed
in MMe cells (REN and MMP) following 2 h stimulation with
TNF-a (4 ng/mL) or treatment with the exportin-1 inhibitor
LMB (1 ng/mL) by HCA of the fluorescence signal associated to
p65RelA immunostaining. As shown in Fig. 1C, in untreated
REN and MMP cells, the nuclear/cytoplasmic shuttling rate of
p65RelAwas prevalently found shifted toward the cytoplasm. Both
TNF-a and LMB altered the nuclear/cytoplasmic distribution,
inducing NF-nB nuclear accumulation and revealing that these
complexes undergo dynamic nuclear-cytoplasmic shuttling.
As expected, exposure of HMC to amosite fibers induced NF-nB
DNA binding, whereas transfection of SV40, a well-known
carcinogen cofactor of mesothelioma (27), did not affect NF-nB
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activity in HMC nor MMe cells (data not shown). Treatment of
HMC with 5 Amol/L Bay 11-7082 was not cytotoxic; however, as
previously reported (20), HMC exposure to a low density of
amosite fibers (2.5 Ag/cm2) induced cytotoxicity potentiated by
5 Amol/L Bay 11-7082 (P = 0.0001). In contrast, Bay 11-7082
alone exerted cytotoxicity in both REN and MMP cells (Fig. 2A).
We have previously shown that HMC transfected with SV40 DNA
and exposed to amosite fibers according to the long-term exposure
undergo cell transformation and foci formation (20). Over the 60-
day time span required for full cell transformation, transformed
HMC became progressively insensitive to amosite cytotoxic effect.
Bay 11-7082 significantly increased their sensitivity to amosite,
consistent with a role for NF-nB signaling in asbestos-dependent
transformation of HMC (Fig. 2A). The same transformed cells
derived from foci displayed NF-nB in activated, phosphorylated
form andNF-nBDNA binding activity (Fig. 2B).We conclude that
NF-nB activity, elicited by amosite in HMC, is constitutive inMMe
cells, providing survival signalingboth in normal and transformed
HMC, analogously to MMe cells.
Bortezomib inhibits NF-kB activity in MMe cells. Based on
the observation that NF-nB is constitutively activated in MMe
cell lines, we tested the effects on these cells of the proteasome
inhibitor Bortezomib that inhibits NF-nB activity by preventing
InB degradation in different cancer models (16). As assessed by
EMSA, 24 h exposure of REN cells to either 25 or 100 nmol/L
Bortezomib decreased NF-nB DNA binding activity in a dose-
dependent manner (Fig. 3A).
The effect of Bortezomib on NF-nB activity by nuclear
translocation analysis was conducted. In REN and MMP cells, a
prevalent cytoplasmic localization was observed; however,
following 1 h of TNF-a stimulation, NF-nB massively relocal-
ized to the nucleus in both cell types, consistently with its
activation (Fig. 3B and C). Cytokine-induced nuclear translo-
cation was almost completely prevented by pretreatment with
both the known irreversible inhibitor of InB-a phosphorylation
Bay 11-7082 or Bortezomib. Both Bortezomib and Bay 11-7082
as single agents induced a slight increase of NF-nB nuclear
translocation signal in both cell lines. Visual inspection of fields
acquired by HCA suggested that this effect could be due, for
Bortezomib, to cell-cycle block induction, resulting in the
accumulation of mitotic cells (in particular for REN), which
have no nuclear envelope, together with the induction of
Fig. 1. NF-nB activity in mesothelial
and mesothelioma cells. A, EMSA analysis
of mesothelial (HMC) and mesothelioma
(MMB, REN, andMMP) cells in the
presence of HGF and Bay11-7082. Murine
liver progenitor cells (MLP29) were as
controls of HGF responsiveness. CTRL,
EMSA in the absence of protein. B, EMSA
analysis on nuclear extracts from the
indicated cells as described in Materials
and Methods. Before lysis, cells were
treated with the indicated panel of inhibitors
of intracellular activities and effectors.The
compounds were inhibitors of: tyrosine
kinase activity (Genistein), Src (PP2),
Erk1/2 (PD98059), PI3K (Wortmannin),
and p38 (SB203580). CTRL, EMSA in
the absence of protein. ^ , no treatment.
COLDPROBE, incubated with unlabeled
oligonucleotide probe. C, REN and MMP
cells were treated with1ng/mL LMB or
stimulated with 4 ng/mLTNF-a, alone or
in combination for 2 h. Cells were fixed,
immunostained with anti ^ NF-nB (p65RelA)
antibody, and counterstained with DAPI.
NF-nB nuclear translocation index was
measured by HCA and expressed as the
difference between nuclear and cytoplasmic
NF-nB ^ related fluorescence intensity.
Columns, means of at least three
replicates; bars, SD.
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apoptosis. Bay 11-7082 was also found to induce cell death
(Fig. 2A), associated with altered spreading and actin cytoskel-
eton remodeling, as already reported in other cellular models
(28). Finally, a slight increase in the mean NF-nB translocation
value was observed in the overall cell population; this could be
due to the sensitivity of the nuclear translocation parameter,
which can be affected by morphologic alterations induced by
treatment, such as mitosis, cell spreading, apoptosis, or
cytotoxicity calculated by imaging approach.
Taking into account those morphologic alterations, both
Bortezomib and Bay 11-7082 alone did not significantly modify
the NF-nB nuclear translocation value in basal conditions.
However, the two compounds efficiently inhibited cytokine-
induced NF-nB nuclear translocation and induced cytotoxicity
both in basal conditions (MMe) and when exposed to asbestos
fibers (HMC and MMe).
These results confirm that Bortezomib significantly reduces
NF-nB nuclear translocation and, in turn, its DNA binding
activity at the same extent of Bay-117082, suggesting a specific
NF-nB targeting.
Bortezomib induces MMe cell death, G2-M cell cycle blockade,
and apoptosis. The cytotoxic effect of Bortezomib in MMe cells
was determined by MTT assay (29). Exposure to Bortezomib for
24 h resulted in a remarkable dose-dependent cytotoxic effect.
The estimated EC50 values were 18.6 nmol/L (SD, 3.6) and
51.4 nmol/L (SD, 18.8) for REN and MMP cells, respectively
(data not shown). In contrast, HMC viability was not affected
by Bortezomib treatment.
The effects of Bortezomib on cell cycle and apoptosis
induction were tested in REN and MMP cells by HCA. MMe
Fig. 3. Effects of Bortezomib on NF-nB binding activity and cytokine-induced
NF-nB nuclear translocation in MMe cells. A, NF-nBDNA binding activity tested
by EMSA upon treatment of REN cells with Bortezomib at 25 and100 nmol/L for
24 h. B and C, nuclear translocation analysis. REN (B) and MMP (C) cells were
treated with1 Amol/L Bortezomib or 50 Amol/L Bay11-7082 for 4, 8, or 24 h and
then stimulated or not for the last hour with 4 ng/mLTNF-a. Cells were fixed,
immunostained with anti ^ NF-nB (p65RelA) antibody, and counterstained with
DAPI. NF-nB nuclear translocation index was measured by HCA and expressed
as the difference between nuclear and cytoplasmic NF-nB ^ related fluorescence
intensity. Columns, means of at least three replicates; bars, SD. *, P < 0.05;
**, P < 0.01.
Fig. 2. Activated form of NF-nB exerts a prolonged cell survival after amosite
exposure. A, MTT assay on the indicated cells, treated with 5 Amol/L Bay11-7082
(white columns), exposed to 2.5 Ag/cm2 amosite fibers alone (gray columns), or in
the presence of Bay11-7082 (black columns). Columns, means of at least three
replicates; bars, SD. B, immunoblotting and EMSA onmesothelial cells (HMC) and
onmesothelial cells derived from foci (HMC-foci), upon long-term exposure to
amosite (see Materials and Methods). P-p65, phosphorylated (activated) form of
p65relA NF-nB subunit. h-actin, loading control.
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cells were exposed to increasing doses of Bortezomib (ranging
from 3 to 800 nmol/L) for three time points (24, 48, and 72 h).
For each concentration, the percentage of remaining cells with
respect to untreated controls, together with the percentages of
positively stained cells for cyclin B1, BrdUrd, and active
caspase-3 were calculated and reported in dose-response curves.
Interestingly, the concentrations at which Bortezomib exerts its
antiproliferative activity were found to be consistent with the
therapeutic dose ranges (30).
In REN cells, Bortezomib inhibited cell growth at 24 h by
inducing a G2-M cell cycle block, with an estimated EC50 of
33 nmol/L (Fig. 4A, left). This was confirmed by the accumulation
of cyclin B1–positive cells and overall cell number decrease (EC50
of 38 nmol/L). In parallel, a decrease in cells engaged in active
S-phase (BrdUrd, EC50 = 57 nmol/L) and relevant apoptosis
induction (active caspase-3, EC50 = 65 nmol/L) were also
evident. At 48 h, either cyclin B1–stained cells and the overall
cell number dramatically decreased at doses above 50 nmol/L,
in parallel with an increase of apoptotic cells. After 72 h of
treatment, HCA profiles of REN cells indicated a massive cell
loss at Bortezomib doses above 25 nmol/L, and the few
remaining cells were apoptotic. The biphasic behavior of cyclin
B1 curves at 48 and 72 h (first increasing and decreasing at
higher doses) indicates that cells progressively undergo
apoptotic cell death from an early cycle block in the G2-M
phase. These data indicate that Bortezomib antiproliferative
activity on REN cells mainly occurs upon the induction of the
G2-M block followed by massive apoptosis.
Fig. 4. Bortezomib induces cell cycle
block and apoptosis in REN and MMP cells.
A, REN andMMP cells were treated with
increasing concentrations of Bortezomib
(ranging from 3 to 800 nmol/L) for 24,
48, or 72 h and then processed for
immunofluorescence and HCA. For each
concentration, the number of cells scored
in10 fields was reported as percentage
with respect to untreated controls (n)
counted on the basis of their nuclear DAPI
fluorescence.The percentages of cells
positively stained for BrdUrd incorporation
(x), cyclin B1 (4), and active caspase-3
(o) were also calculated. Points, means
of at least three replicates; bars, SD. B,
immunoblotting analysis on REN, MMP,
and HMC cell lysates after 24 h exposure
to10 to100 nmol/L Bortezomib. DPARP,
89-kDa cleaved fragment.
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In MMP cells, despite the decrease in BrdUrd incorporation
(EC50 = 71 nmol/L) and the induction of apoptosis (EC50 =
200 nmol/L) at 24 h, the cell number did not change
significantly (Fig. 4A, right). Moreover, only a slight accumu-
lation of G2-M cells was observed at higher doses. After 48 and
72 h, these perturbation trends of all parameters were
emphasized, although a significant cell number decrease was
achieved only at 72 h (EC50 = 100 nmol/L). This indicates that
Bortezomib inhibited cell proliferation, as confirmed by a
decrease in BrdUrd incorporation, albeit with less efficacy with
respect to REN cells. Cell-cycle and apoptotic effects on both
cell lines were confirmed by flow cytometry analysis of DNA
content, done in parallel (data not shown).
To further assess the proapoptotic activity of Bortezomib,
Western blot analysis of PARP cleavage was done on cell lysates
from REN, MMP, and HMC cells treated with 10 to 100 nmol/L
of Bortezomib for 24 h. As shown in Fig. 4B, cleavage of PARP
occurred in REN and MMP cells starting at the dosage of 10 and
25 nmol/L, respectively. This confirmed the HCA profiles of
apoptosis induction. PARP cleavage was undetectable in HMC
cells.
Bortezomib inhibits tumor growth in an in vivo model of
malignant mesothelioma. To determine if exposure to Borte-
zomib could inhibit MMe tumor growth in vivo, xenografts of
REN cells were generated in nude xid mice. REN cells were
injected i.p. into mice and allowed to engraft for 3 days. Mice,
randomly distributed into groups of four to eight animals, were
then treated with Bortezomib at doses of 0.5 and 1.0 mg/kg,
given by i.p. bolus injection twice weekly for 4 weeks. Control
animals received the same schedule of vehicle (saline) alone.
Mice were sacrificed on day 30 after tumor cell injection for
measurement of ascites volume, removal and weighing of all
tumor foci, and notation of gross tumor involvement of the
diaphragm for each animal. Two in vivo trials were carried out,
and Bortezomib mediated inhibition of tumor growth (Fig. 5).
In particular, at 1 mg/kg Bortezomib, a significant inhibition of
tumor weight was noted in both trials (P < 0.05 in trial 1;
P < 0.01 in trial 2). In trial 2, a significant inhibition of tumor
growth was also observed at the lower dose of 0.5 mg/kg
(P < 0.01).
Fig. 5. Antitumor activity of Bortezomib in the mesothelioma xenograft murine
model. About 1.3 to1.6 107 REN cells were injected i.p. in nude xid mice;
treatment with Bortezomib was started 3 days after tumor inoculation to allow
engraftment. Doses evaluated were 0.5 and1mg/kg/day, given twice a week
on a Monday/Thursday schedule for 4 wks. Control untreated animals received
single i.p. bolus injection of vehicle alone.Tumor weight at the time of sacrifice
(day 30) is indicated. Columns, means for the two different trials done; bars,
SD. *, P < 0.05; **, P < 0.01.
Fig. 6. Inhibition of diaphragmatic tumor growth by Bortezomib in REN
tumor-bearing mice. Representative pictures from trial 2. At the time of sacrifice,
diaphragm involvement was evaluated by resection in each animal. Underside of
diaphragms are shown. A, in untreated (control) mice, large, bulky tumor are
evident. B, in the 0.5-mg/kg group, few tumor nodules are seen. C, no gross
evidence of tumor involvement in the1-mg/kg group.
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Based on the recorded volume of ascites, these data were
assessed on a dichotomous scale, assigning trace or greater
volumes as positive and zero volumes as negative. Analysis
across trials showed that 88.5% of control animals presented
positive for ascites, compared with 46.0% in the 0.5-mg/kg
group and 17.4% in the 1-mg/kg group (m2 = 18.06, P < 0.0001).
Finally, treatment with Bortezomib dramatically reduced
diaphragm involvement, with none of the 1-mg/kg dose group
presenting any involvement and 15.4% of the 0.5-mg/kg dose
group showing mild involvement only. In the control group,
55.5% of the mice presented with massive, 33.3% with
moderate/mild, and 11.1% with no apparent involvement
(m2 = 24.50, P < 0.0001; Table 1). Figure 6 shows the
abdominal surface of the diaphragms from all animals in trial
2. Finally, only Bortezomib-treated animals seemed healthy
throughout each of the studies, and no significant weight loss
was noted in any drug-treated mice.
Discussion
This report provides evidence supporting a role for NF-nB
activation and nuclear translocation in inducing resistance to
cell death of HMC and MMe cells exposed to asbestos fibers
and contributing to HMC transformation. Moreover, inhibition
of NF-nB constitutive activation in MMe cells by Bortezomib
resulted in in vitro cytotoxicity along with apoptosis and in vivo
tumor regression.
NF-nB is well known to be activated upon exposure to a
variety of extracellular stimuli as oxidative stress, hypoxia,
inflammatory cytokines, and others (5). The presence of these
factors in the tumor microenvironment is consistent with the
finding of a constitutive NF-nB activation in mesothelioma
tumor cells.
Our results provide further evidence that asbestos fibers, the
main established cause of MMe, cause the translocation of
NF-nB p65 subunit into the nucleus and increase NF-nB DNA
binding activity in pleural mesothelial cells, in accordance with
a number of previous studies (31–39). Interestingly, a recent
work shows that in HMCs, TNF-a induces cell survival, and
resistance to asbestos induced cytotoxicity via NF-nB, indicating
a critical role for this transcriptional factor in cells exposed to
asbestos (40). Our paper is in accordance with these data and is
the first evidence of the role of NF-nB as a survival factor in
MMe cells.
SV40 infection has been recently considered as a relevant co-
causative agent of MMe (20, 41–45) by activating several
survival signaling pathways (26, 46–48).
According to our previous study (20), we exploited an in vitro
model of SV40/fibers combined transforming process to verify
if NF-nB can contribute to a fully transformed phenotype of
HMC, via progressive resistance to asbestos fibers. Our results
clearly show that NF-nB acts as an additional survival factor for
HMC exposed to asbestos, leading to the transformation and
for MMe cells in basal conditions. These results provide the
evidence that NF-nB plays a role in MMe oncogenesis as in
many other human tumors (4).
PI3K/Akt signaling pathway has been implicated in NF-nB
activation (reviewed in ref. 49), and more recently, it has been
shown that NF-nB is activated independently by Akt (50),
whereas the pathway leading to NF-nB activation has been
linked to cell type variations (51). We show here that both in
HMC and in MMe cells, NF-nB activity is not related to PI3K/
Akt signaling. Nevertheless, our results do not clarify which
signaling pathway is responsible for NF-nB activity in all cells
investigated. Given that neither mitogen-activated protein
kinase inhibition (Erk1 and 2 or p38) nor wortmannin affects
NF-nB activity, in contrast to what is observed in other cell types
(52), the underlying pathway activating NF-nB in these cells is
currently under investigation.
Platelet-derived growth factor (PDGF) and epidermal growth
factor (EGF) are candidates for NF-nB activation, but our
findings show that neither the general tyrosine kinase inhibitor
(genistein) nor the specific Src inhibitor (PP2) affects NF-nB
activity. In contrast, we provided evidence that HGF leads to
NF-nB activation in epithelial MLP29 cells, albeit neither
related to survival nor to PI3K/Akt activity (23). This does not
occur in HMC or MMe cells, where HGF exerts its antiapoptotic
effect independently to NF-nB activation.
Cells derived from the foci of SV40-HMC cultures are
significantly more resistant to asbestos than HMC, whereas
Bay 11-7082 restores sensitivity to amosite more significantly in
HMC than in foci cells. Likewise, although sensitivity to
asbestos of MMe cells was similarly low, despite the presence
or absence of SV40, Bay 11-7082 was more effective in SV40-
negative REN than in SV40-positive MMP. The additive survival
effects due to SV40-dependent Akt activation, as reported for
other tumors (53), and the higher basal NF-nB activity were
possibly responsible for these discrepancies. Altogether, our
results indicate that NF-nB plays an additional role on the
induction of cytotoxicity resistance to asbestos in HMC on top
of the parallel well-known effect on tumor progression of SV40-
dependent Akt activation (54).
Our results confirm that the NF-nB inhibitor Bay 11-7082
leads to specific MMe cells death, whereas NF-nB inhibition has
been recently discussed as a novel target for the treatment of
human tumors (55, 56). This prompted us to hypothesize the
use of compounds aimed at NF-nB inhibition as novel tailored
targeted therapy for MMe and we verified if Bortezomib
inhibition of NF-nB could induce apoptotic cell death in this
neoplasm. Although the proteasome-inhibitory activity of
Table 1. In vivo evaluation of the ability of
Bortezomib to prevent diaphragmatic tumor
formation in a model of malignant mesothelioma
Diaphragm involvement Bortezomib dose
Control
(0 mg/kg)
0.5 mg/kg 1.0 mg/kg
Massive 5/9 0/13 0/11
Moderate 1/9 0/13 0/11
Mild 2/9 2/13 0/11
None 1/9 11/13 11/11
NOTE: About 1.3 to 1.6  107 REN cells were injected i.p. in nude
xid mice; 3 d after tumor inoculation treatment with Bortezomib at
dosages of 0.5 or 1.0 mg/kg/day was started. Drug was given i.p.
twice weekly for 4 wk. Control animals received single i.p. bolus
injection of vehicle alone. Two different trials using the same
experimental conditions were done. The table summarizes the
antitumor activity of Bortezomib as assessed by the extent of
diaphragm involvement (classified as none, mild, moderate, or
massive; see Materials and Methods).
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Bortezomib may well interfere with many other apoptotic
signaling pathways (53), we focused on NF-nB inhibition as a
relevant therapeutic target in MMe cells.
NF-nB constitutive activation in MMe induces signals leading
to cell proliferation and inhibition of apoptosis of these tumor
cells. EMSA shows that in MMe cells, NF-nB is constitutively
bound to DNA, although immunostaining of p65RelA appar-
ently indicates that in untreated cells, NF-nB complexes
primarily localize to the cytoplasm. However, data from EMSA
and NF-nB translocation are only apparently in conflict:
treatment with the exportin-1 inhibitor LMB induces NF-nB
nuclear accumulation, revealing that these complexes undergo
dynamic nuclear-cytoplasmic shuttling, as previously reported
(57). In steady state, the majority of NF-nB complexes localizes
to the cytoplasm bound to InB-a as result of a shift in the
dynamic equilibrium toward the nuclear export. The effect of
Bortezomib on NF-nB nuclear translocation was evaluated in
REN and MMP cells by HCA; we found that, upon cytokine
stimulation conditions, which mimic the in vivo tumor
microenvironment (4), Bortezomib efficiently inhibits NF-nB
nuclear translocation. We used TNF-a to induce NF-nB
activation in REN and MMP cells. Treatment of MMe cells
with Bay 11-7082, a specific InB-a stabilizer, also resulted in
the inhibition of cytokine-induced NF-nB nuclear transloca-
tion, as expected. All in all, our data indicate that in MMe cells
(but not in HMC), NF-nB dynamically shuttles across the
nuclear envelope, and our data confirm that, despite a
prevalent cytoplasmic localization in steady state, a subset of
NF-nB complexes actually localizes to the nucleus and is
responsible for the constitutive basal activation of NF-nB target
genes.
Bortezomib induces apoptosis in MMe cells, as evidenced by
PARP cleavage that correlates with a marked reduction in NF-nB
activity and cell cycle arrest (15, 58). Although our in vitro
results clearly suggest that Bortezomib exerts its effects on MMe
cells via NF-nB, one cannot exclude the fact that also the
modulation of further survival pathways may be involved.
Our in vivo results were generated in a model that mimics
some clinical features of mesothelioma, including the forma-
tion of malignant effusion and progressive i.p. tumor spread.
The ability of Bortezomib to abrogate the spread of the tumor
to the diaphragmatic surface as well as the formation of
malignant effusions, along with its safety, supports the use of
Bortezomib in the treatment of MMe and suggests a role for the
administration of this agent for therapeutic purposes. The role
of NF-nB in conferring HMC cellular resistance to apoptosis
and MMe carcinogenesis might suggest the hypothesis that
Bortezomib administration could be pursued as a potential
chemopreventive treatment for people exposed to asbestos
fibers. On the basis of these preclinical findings, a phase II
clinical trial with Bortezomib as a single agent for patients with
relapsed MMe is currently ongoing across Europe along with a
European Organization for Research and Treatment of Cancer
phase II trial incorporating Bortezomib and cisplatin combi-
nation therapy planned.
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